Treatment Options for Metastatic Castration-Resistant Prostate Cancer
Introduction to Alternative Treatments
- The National Comprehensive Cancer Network recommends enzalutamide as the preferred alternative treatment option for metastatic castration-resistant prostate cancer (mCRPC) in patients who cannot use spironolactone with abiraterone and prednisone 1, 2
Reason for Avoiding Spironolactone with Abiraterone
- Spironolactone should be avoided when taking abiraterone because it can interfere with abiraterone's mechanism of action and potentially reduce its efficacy, according to the National Comprehensive Cancer Network 3
- Abiraterone requires concurrent steroid administration to manage mineralocorticoid excess side effects, including hypertension, hypokalemia, and peripheral edema, as recommended by the National Comprehensive Cancer Network 3, 4
Primary Alternative Treatment Options
- Enzalutamide is a first-line alternative to abiraterone for mCRPC with strong evidence supporting its use, according to the National Comprehensive Cancer Network 1, 2
- The recommended dose of enzalutamide is 160 mg per day, as stated in the Journal of Clinical Oncology 5
- Enzalutamide does not require concurrent steroid administration, as noted in The Journal of Urology 2
- Potential side effects of enzalutamide include fatigue, hypertension, and rarely seizures, according to The Journal of Urology and the National Comprehensive Cancer Network 2, 3
Chemotherapy Options
- Docetaxel-based chemotherapy is a standard treatment option for mCRPC patients with good performance status who have progressed on hormonal therapy, as recommended by The Journal of Urology 6
- Docetaxel is particularly appropriate for patients with symptomatic disease or visceral metastases, according to the National Comprehensive Cancer Network and The Journal of Urology 1, 6, 7
Other Treatment Options
- Radium-223 is specifically indicated for patients with symptomatic bone metastases without known visceral disease, as stated in The Journal of Urology 6, 2
- Radium-223 can be used in patients with good performance status who have not received prior docetaxel, according to The Journal of Urology 6
- Radium-223 improves overall survival while targeting bone metastases, as noted in The Journal of Urology 6
Monitoring Considerations
- Regular monitoring of liver function, potassium levels, and blood pressure is essential with all hormonal therapies, as recommended by the National Comprehensive Cancer Network 3, 4
- Cardiac monitoring is particularly important in patients with pre-existing cardiovascular disease, according to the National Comprehensive Cancer Network 3
- PSA response should be evaluated regularly, but treatment decisions should not be made solely on PSA changes, as stated by the National Comprehensive Cancer Network and The Journal of Urology 1, 4